Application of lncRNA in the diagnosis and treatment of lung adenocarcinoma

• Main Authors: DU ZEDONG, LIAO HONGFEI, LI GUANGHUA, XU HONGYU, MENG RONGQIN, LIU XIANGUO, ZHANG GUANGYU, HE LIANG
• Format: Patent
• Language: Chinese; English
• Published: 11.08.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The present invention discloses application of lncRNA in the diagnosis and treatment of lung adenocarcinoma. The lncRNA is AC018890.6, which is highly expressed in lung adenocarcinoma tissues, and proliferation, migration and invasion of lung adenocarcinoma cells can be affected by changing the expression level of AC018890.6; it is suggested that whether a subject has lung adenocarcinoma or the risk of lung adenocarcinoma can be judged by detecting the expression level of ACO18890.6, and the lung adenocarcinoma can be treated by targeting ACO18890.6. 本发明公开了lncRNA在肺腺癌诊疗中的用途，所述lncRNA为AC018890.6，AC018890.6在肺腺癌组织中高表达，且改变AC018890.6的表达水平可以影响肺腺癌细胞的增殖、迁移和侵袭，提示可以通过检测AC018890.6在受试者中的表达水平，可以判断受试者是否患有肺腺癌或者患肺腺癌的风险，以及靶向AC018890.6可以治疗肺腺癌。